HOXC10 is Associated with Cancer Progression and Poor Prognosis in Renal Cell Carcinoma Patients
Abstract
remain unclear. This study investigates its clinical significance, immune associations, and metabolic mechanisms in RCC. Methods: We
analyzed TCGA-KIRC transcriptomic and clinical data, validating protein expression via immunohistochemistry (IHC) on local samples.
Bioinformatics tools were used for survival analysis, immune infiltration deconvolution, drug sensitivity prediction. Results: HOXC10 acts as
a protective prognostic factor in RCC. High expression significantly correlates with early clinicopathological stages and prolonged survival,
demonstrating strong long-term predictive accuracy (10-year OS AUC = 0.807). High HOXC10 expression is associated with a favorable tumor immune microenvironment (e.g., increased M1 macrophages and activated NK cells) and predicts enhanced sensitivity to targeted therapies like rapamycin and sorafenib. Conclusion: HOXC10 is a novel, protective biomarker in RCC. Its association with favorable immune
infiltration, and drug sensitivity highlights its potential for long-term prognostic assessment and personalized therapy.
Keywords
Full Text:
PDFReferences
[1] Young, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez, C., Bex, A., Powles, T., and Szabados, B. (2024). Renal cell carcinoma.
Lancet 404, 476491. 10.1016/S0140-6736(24)00917-6.
[2] Rose, T.L., and Kim, W.Y. (2024). Renal Cell Carcinoma: A Review. JAMA 332, 10011010. 10.1001/jama.2024.12848.
[3] Lobo, J., Ohashi, R., Amin, M.B., Berney, D.M., Comperat, E.M., Cree, I.A., Gill, A.J., Hartmann, A., Menon, S., Netto, G.J., et al. (2022).
WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology 81, 426438. 10.1111/his.14700.
[4] Iskandar, A.S., Zarrabi, K.K., and Tester, W.J. (2024). Renal cell carcinoma: entering the age of biomarkers. Can J Urol 31, 1192111930.
[5] Siegel, R.L., Giaquinto, A.N., and Jemal, A. (2024). Cancer statistics, 2024. CA Cancer J Clin 74, 1249. 10.3322/caac.21820.
[6] Ghoreifi, A., Vaishampayan, U., Yin, M., Psutka, S.P., and Djaladat, H. (2024). Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review. JAMA Oncol 10, 240248. 10.1001/jamaoncol.2023.5269.
[7] Powles, T., Albiges, L., Bex, A., Comperat, E., Grunwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., et
al. (2024). Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 35, 692706.
10.1016/j.annonc.2024.05.537.
[8] Hwang, J.H., Seok, O.S., Song, H.R., Jo, J.Y., and Lee, J.K. (2009). HOXC10 as a potential marker for discriminating between amnionand decidua-derived mesenchymal stem cells. Cloning Stem Cells 11, 269279. 10.1089/clo.2008.0068.
[9] Kato, H., Ario, T., Kishida, T., Tadano, M., Osawa, S., Maeda, Y., Takakura, H., and Izawa, T. (2021). Homeobox A5 and C10 genes
modulate adaptation of brown adipose tissue during exercise training in juvenile rats. Exp Physiol 106, 463474. 10.1113/EP089114.
[10] Fang, J., Wang, J., Yu, L., and Xu, W. (2021). Role of HOXC10 in Cancer. Front Oncol 11, 684021. 10.3389/fonc.2021.684021.
[11] Li, Y., Lei, H., Hai, R., Shu, G., Yan, W., and Yin, G. (2022). HOXC10 promotes carboplatin resistance of ovarian cancer by regulating
ABCC3. Am J Cancer Res 12, 46024621.
[12] Enteghami, M., Ghorbani, M., Zamani, M., and Galehdari, H. (2020). HOXC10 is significantly overexpressed in colorectal cancer. Biomed Rep 13, 18. 10.3892/br.2020.1325.
[13] Li, K., Yang, B., Du, Y., Ding, Y., Shen, S., Sun, Z., Liu, Y., Wang, Y., Cao, S., Ren, W., et al. (2024). The HOXC10/NOD1/ERK axis
drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. Bone Res 12, 47. 10.1038/s41413-024-00350-8.
[14] Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V.,
et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173,
400416 e411. 10.1016/j.cell.2018.02.052.
[15] Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D.Y., Larkin, J., and Ficarra, V. (2017). Renal
cell carcinoma. Nat Rev Dis Primers 3, 17009. 10.1038/nrdp.2017.9.
DOI: http://dx.doi.org/10.70711/pmr.v3i7.9413
Refbacks
- There are currently no refbacks.
